FIELD: medicine.
SUBSTANCE: invention relates to a method of therapeutic treatment and/or improvement of the condition of a patient with sepsis. A method of therapeutic treatment and/or improvement of the condition of a patient with sepsis involves administering a medicinal product containing thrombomodulin as an active ingredient, where the said medicinal product is administered to a patient whose International Normalized Ratio (INR) value is greater than 1.4 immediately prior to administration, where the term “immediately before administration” means a period of 1 hour, calculated retrospectively from the start of administration of a medicinal product containing thrombomodulin, where the medicinal product is administered to a patient whose platelet count is greater than 30,000/mm3 just before administration.
EFFECT: above invention provides a method of effective therapeutic treatment and/or improvement in sepsis accompanied by coagulopathy.
11 cl, 1 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY MONITORING IN TREATMENT WITH BINDING AGENT AGAINST ADRENOMEDULLIN (ADM) | 2018 |
|
RU2776811C2 |
| ANTI-ORAI1 ANTIBODY | 2015 |
|
RU2724742C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 | 2019 |
|
RU2783762C2 |
| TREATMENT OF HEADACHE WITH EXCESSIVE USE OF DRUGS WITH ANTIBODIES TO CGRP OR CGRP-R | 2020 |
|
RU2826186C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| MONOCLONAL ANTIBODY TO ACTIVATED PROTEIN FROM HUMAN AND PRODUCTION AND USE THEREOF | 2021 |
|
RU2824515C1 |
| ANTITUMOR AGENT AND A METHOD OF ITS EVALUATION | 2019 |
|
RU2803148C2 |
| NEW FAB-FRAGMENT OF HUMAN NGF ANTIBODY | 2016 |
|
RU2729825C2 |
| VERSIONS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY | 2018 |
|
RU2813990C2 |
